Gestiphar SRL
2.0 FTEGestiphar reported total assets of €3.17m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Aug 2026), with 2 full-time equivalents.
The score of Gestiphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +94 % Total assets +28 % Headcount (avg FTE) +100 %
Accounts of the company itself (not consolidated).
The full file covers 12 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Gestiphar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Aug 2026
- Year ended 31 Dec 2024filed on 30 Sep 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
Gestiphar's financial analysis
- Solvency22.9%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Gestiphar
Gestiphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0538.550.235
- VAT number
- BE0538550235
- Peppol
- Registered · 0208:0538550235 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Sep 2013
- Registered office
- 6044 Charleroi
- Size
- Micro · 2.0 FTE
- Latest accounts
- 2025 · filed on 26 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Gestiphar (SRL) has been based in Charleroi since 2013, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 4,135 € and equity of 724,711 €; its revenue is not published. With 2.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 22.9%, below the median of its sector (41.5%).
Companies similar to Gestiphar
Companies in the same business, of comparable size and area, outside its group.
- PG Pharmaceuticals Business and other management consultancy activities Opwijk · balance sheet €1.86m
- FDM Pharma Retail sale of pharmaceutical products Charleroi · balance sheet €2.84m
- Alphar Leglise Retail sale of pharmaceutical products Léglise · balance sheet €2.53m
- Tervest Retail sale of pharmaceutical products Tervuren · balance sheet €4.38m
- GFI Retail sale of pharmaceutical products Mechelen · balance sheet €4.60m
- Pharmacie Ronlez Retail sale of pharmaceutical products Ath · balance sheet €1.96m
- S.P.S. Retail sale of pharmaceutical products Gingelom · balance sheet €6.00m
- Management Aelbers Retail sale of pharmaceutical products Dilsen-Stokkem · balance sheet €1.27m
Frequently asked questions about Gestiphar
What is the revenue of Gestiphar?
Gestiphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Gestiphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0538550235 for Gestiphar, if the company is VAT-registered. Its company number (CBE) is 0538.550.235.
Where is the registered office of Gestiphar?
According to the CBE register, the registered office of Gestiphar is in 6044 Charleroi.
What is the equity of Gestiphar?
At the close of the 2025 financial year, the equity of Gestiphar amounts to 724,711 €, a solvency of 22.9% of total assets.
How many people work at Gestiphar?
2.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Gestiphar?
The register lists 2 active mandates at Gestiphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Gestiphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →